title: The intracerebroventricular injection of rimonabant inhibits systemic lipopolysaccharide-induced lung inflammation.
abstract: We investigated the role of intracerebroventricular (ICV) injection of rimonabant (500ng), a CB1 antagonist, on lipopolysaccharide ((LPS) 5mg/kg)-induced pulmonary inflammation in rats in an isolated perfused lung model. There were decreases in pulmonary capillary pressure (Ppc) and increases in the ((Wet-Dry)/Dry lung weight)/(Ppc) ratio in the ICV-vehicle/LPS group at 4h. There were decreases in TLR4 pathway markers, such as interleukin receptor-associated kinase-1, IκBα, Raf1 and phospho-SFK (Tyr416) at 30min and at 4h increases in IL-6, vascular cell adhesion molecule-1 and myeloperoxidase in lung homogenate. Intracerebroventricular rimonabant attenuated these LPS-induced responses, indicating that ICV rimonabant modulates LPS-initiated pulmonary inflammation.
authors: Department of Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, United States.
authors: Arnold
authors: A
authors: Johnson
authors: Department of Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, United States.
authors: Paul H
authors: PH
authors: Neumann
authors: Department of Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, United States.
authors: Jianya
authors: J
authors: Peng
authors: Department of Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, United States.
authors: Janey
authors: J
authors: James
authors: Department of Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, United States.
authors: Vincenzo
authors: V
authors: Russo
authors: Department of Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, United States.
authors: Hunter
authors: H
authors: MacDonald
authors: Department of Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, United States.
authors: Nancy
authors: N
authors: Gertzberg
authors: Department of Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, United States. Electronic address: carlos.feleder@acphs.edu.
authors: Carlos
authors: C
authors: Feleder
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D016207:Cytokines / Q000235:genetics / Q000378:metabolism; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004333:Drug Administration Routes; D004334:Drug Administration Schedule; D007276:Injections, Intraventricular; D008070:Lipopolysaccharides / Q000633:toxicity; D008168:Lung / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008297:Male; D009195:Peroxidase / Q000378:metabolism; D010880:Piperidines / Q000008:administration & dosage*; D011014:Pneumonia / Q000139:chemically induced / Q000517:prevention & control*; D011654:Pulmonary Edema / Q000139:chemically induced / Q000517:prevention & control; D011720:Pyrazoles / Q000008:administration & dosage*; D051381:Rats; D017207:Rats, Sprague-Dawley; D000077285:Rimonabant; D015398:Signal Transduction / Q000187:drug effects; D013997:Time Factors; D051197:Toll-Like Receptor 4 / Q000378:metabolism
chemical_list: D000893:Anti-Inflammatory Agents; D016207:Cytokines; D008070:Lipopolysaccharides; D010880:Piperidines; D011720:Pyrazoles; C495347:Tlr4 protein, rat; D051197:Toll-Like Receptor 4; D009195:Peroxidase; D000077285:Rimonabant
keywords: CB(1) receptor; Inflammation; Lipopolysaccharide; Pulmonary edema; Rimonabant; TLR4